

IN THE CLAIMS:

Please amend claims 1 and 3 and cancel claims 2 and 4. Please add new claim 9.

1. A pharmaceutical composition ~~vaccine~~ comprising:  
  
a biocompatible carrier for injection or infusion, and pharmaceutical composition comprising  
an isolated and purified N-terminal fragment of agglutinin like sequence (als1) cell surface adhesin  
protein obtained from *Candida albicans*, wherein the vaccine produces an effective immune  
response in a patient to ~~block adhesin of Candida albicans to endothelial cells.~~
3. The composition ~~vaccine~~ of Claim 1, wherein the protein is ~~an N-terminal fragment~~  
~~and contains an~~ the adhesin binding site of Candida albicans.
9. The composition ~~vaccine~~ of claim 1 wherein the N-terminal fragment is encoded by  
nucleotides 52 to 1296 of SEQ ID No.7 ~~protein is SEQ ID NO.7.~~